

**Vector pLNCX Containing HLA-B\*1501 Allele****Catalog No. NR-2797****For research use only. Not for human use.****Contributor:**

Ellis L. Reinherz, M.D., Professor of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts

**Manufacturer:**

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

**Product Description:**

The HLA-B\*1501 allele from a human Major Histocompatibility Complex (MHC) Class I human leukocyte antigen (HLA)-homozygous human B-lymphoblastoid cell line (B-LCL) was amplified by PCR, gel purified and cloned into the Clontech Laboratories vector, pLNCX by the International Histocompatibility Working Group (IHWG). The plasmid was produced in *Escherichia coli* DH5 $\alpha$ <sup>TM</sup>-T1<sup>R</sup> cells (Invitrogen<sup>TM</sup>) and extracted using a QIAGEN<sup>®</sup> EndoFree<sup>®</sup> Plasmid Maxi Kit.

Allele:<sup>1</sup> HLA-B\*1501Vector: pLNCXInsert Size: 1.17 kbSelection: Ampicillin (Prokaryotic)/G418 (Eukaryotic)ImMunoGeneTics: [HLA00162](#)GenBank: AF436090

NR-2797 has been qualified for use in bacterial transformations.

**Material Provided:**

Each vial contains 20 to 50 ng of plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

**Packaging/Storage:**

NR-2797 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Vector pLNCX Containing HLA-B\*1501 Allele, NR-2797."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see [www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC<sup>®</sup> and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC<sup>®</sup>, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Pohla, H., et al. "Allelic Variation in HLA-B and HLA-C Sequences and the Evolution of the HLA-B Alleles." Immunogenetics 29 (1989): 297-307. PubMed: 2714852.
2. Choo, S. Y., L. A. Fan, and J. A. Hansen. "Allelic Variations Clustered in the Antigen Binding Sites of HLA-Bw62 Molecules." Immunogenetics 37 (1993): 108-113. PubMed: 8423049.
3. Cox, S. T., et al. "Cloning and Sequencing Full-Length HLA-B and -C Genes." Tissue Antigens 61 (2003): 20-48. PubMed: 12622774.

4. Domena, J. D., et al. "A Small Test of a Sequence-Based Typing Method: Definition of the B\*1520 Allele." Tissue Antigens 44 (1994): 214-224. PubMed: 7871522.
5. Gómez-Casado, E., et al. "Generation of the HLA-B35, -B5, -B16, and -B15 Groups of Alleles Studied by Intron 1 and 2 Sequence Analysis." Immunogenetics 46 (1997): 467-476. PubMed: 9321426.
6. Hildebrand, W. H., et al. "HLA-B15: A Widespread and Diverse Family of HLA-B Alleles." Tissue Antigens 43 (1994): 209-218. PubMed: 7521976.
7. Lin, L., et al. "Further Molecular Diversity in the HLA-B15 Group." Tissue Antigens 47 (1996): 265-274. PubMed: 8773315.
8. Martínez-Laso, J., et al. "Different Evolutionary Pathway of B\*570101 and B\*5801 (B17 Group) Alleles Based in Intron Sequences." Immunogenetics 55 (2004): 866-872. PubMed: 14985876.
9. Nair, R. P., et al. "Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene." Am. J. Hum. Genet. 78 (2006): 827-851. PubMed: 16642438.
10. Román, A., et al. "Generation of HLA-B\*1516/B\*1567/B\*1595 and B\*1517 Alleles (B15 Specific Group) by Transpecies Evolution." Hum. Immunol. 68 (2007): 1001-1009. PubMed: 18191729.

ATCC® is a trademark of the American Type Culture Collection.

